News

Phase 3 trial results presented at AAAAI/WAO 2025 highlight dupilumab's efficacy in reducing itch severity and urticaria activity in CSU patients.

A new qualitative analysis revealed which type of content on acne is trending on the social media platform and how clinicians should respond.

APG990 showed a 60-day half-life and favorable safety, supporting potential 3-6 month maintenance dosing for atopic dermatitis.

“It's so exciting to see all these incredible female talents behind me. I want to give back and I want to help them climb on my shoulders and go higher,” Haws said.

Explore the top headlines of the week including insights from Terri Philips, MD, FAAP, innovations in wound healing, and more.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

In case you missed it, this week we had news about Arcutis’ sNDA for roflumilast in pediatric AD, the current clinical and aesthetic applications of snail mucin, positive results from the CHE delgocitinib trial in China, and more.

This week, we feature top articles from our sister publications on recent clinical trials, practice management, and innovative technology.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of March.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Explore the top headlines of the month including the expanding role of NPs and PAs, a guide to 2025 conferences, and expert insights from Paul Friedman, MD.

Share your thoughts by answering today’s poll and read about these popular aesthetic techniques for lips.

Review our content from the month of February that recognizes patients and clinicians with skin of color.

At a recent Dermatology Times Case-Based Roundtable event, James Q. Del Rosso, DO, discussed the limitations of topical corticosteroids and the benefits of nonsteroidals.

Learn more about the in-depth topics covered in the February 2025 print issue of Dermatology Times.

Today, Dermatology Times recognizes Rare Disease Day in an effort to amplify the voices of the over 300 million individuals affected by rare diseases.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Objective tools like IGA and EASI provide structured severity assessment but often lack patient-reported insights such as itch severity.

Belgian patients receiving biologics had faster response rates compared to phototherapy, systemic, and topical treatments.

Dermatology Times is looking back on the top stories in dermatology from the month of February.

After just 2 weeks of twice-daily use, a pediatric patient saw visually improved skin with no adverse events.

Independent pharmacies are closing at high rates, leaving many communities without essential health care access.

DELTA China follows the success of European and Canadian trials, reinforcing delgocitinib’s potential as a global treatment for CHE.

Nonsteroidal AD therapies are gaining attention due to their rapid effectiveness and ability to offer an alternative to long-term steroid use.

Dermatology Times is recapping our top expert interviews from the month of February.

Christophe Piketty, MD, PHD, provides a deeper look at the promise of nemolizumab in addressing unmet needs faced by patients with atopic dermatitis and prurigo nodularis.

Haws offers advice to female clinicians about leadership, collaboration, and the future of the aesthetics industry.

Christophe Piketty, MD, PHD, discusses the promising efficacy, novel mechanisms, and patient benefits of nemolizumab in targeting IL-31 for atopic dermatitis and prurigo nodularis.

Well Revolution’s partnership with City Chemist highlights how telehealth can sustain small businesses and improve patient care.